Contract Research Solutions (Pulmonary fibrosis model)
Idiopathic pulmonary fibrosis (IPF) is chronic interstitial pneumonia of unknown causes. IPF is characterized by alveolar injury and interstitial inflammation followed by excessive deposition of extracellular matrix and destruction of lung architecture. The mortality rate of IPF is quite high (nearly 70% mortality at 5 years after diagnosis), while the current pharmacological interventions are largely limited.
Bleomycin (BLM)-induced pulmonary fibrosis is the most established disease model for IPF and widely used to investigate the efficacy and/or mechanism of therapeutic candidates.
SMC Laboratories has re-validated BLM-induced pulmonary fibrosis as a murine model translating non-clinical program into clinical practice.
Features and advantages of SMC Laboratories’ BLM-induced pulmonary fibrosis model
- Uniform and reproducible phenotype
- Efficient introduction of BLM by MicroSprayer®
- CT evaluation of fibrotic lesions
- In-life assessment as in clinical studies
- Sampling scheme that allows all analyses in a single mouse
- Maximum information (histology, biochemistry, RT-PCR etc.) with minimum animal number
- Expert histology
- Accumulated knowledge and experience across fibrosis models
- Availability of positive control
- Nintedanib (BIBF 1120)
SMC Laboratories’ contract research will assist you with protocol design to generate reliable results from each study. All tests will be carried out at our own state-of-the-art facility located in Tokyo, Japan.
Sample design to assess the drug efficacy on pulmonary fibrosis:
- Route of drug administration
- po, iv, ip, sc, etc.
- Treatment period
- 2-3 weeks [from day 0 (preventive)/day 7 (therapeutic) to day 20]
- STAM™ mouse at week 6 showing evidence of NASH (increase NAFLD activity score and serum transaminase), similar inclusion criteria to NASH patients.
- Ashcroft score (MT staining), Collagen content (Sircol collagen assay /hydroxyproline assay).
- Ashcroft score (MT staining)
- Immunohistochemical analyses for fibrotic markers
- Lung collagen content (Sircol collagen assay/hydroxyproline assay)
- Cytological analysis
- Cytokine ELISA
Gene expression (Quantitative PCR)
- Fibrosis distribution and density